Chairpersons :

Shishir Shetty, S. D. Banavali, Anil Sanganeria

Reviewer :

Nilesh Lokeshwar

1. First-line ribociclib or placebo combined with goserelin and tamoxifen or a nonsteroidal aromatase inhibitor in premenopausal women with hormone receptorpositive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial Author: Tripathy D. Citation: SABCS Abstract GS2-05

2. Everolimus (EVE) plus endocrine therapy in patients with Estrogen Receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-) advanced Breast Cancer (BC): First- and second-line data from the BOLERO-4 study Author: Fatima Cardoso Citation: Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 1010-1010